Could a common arthritis drug hold off a rare blood cancer?
NCT ID NCT05014646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether leflunomide, a drug used for arthritis, can delay the onset of multiple myeloma in 27 people with high-risk smoldering multiple myeloma. The study includes both African-American and European-American participants to see if the drug works differently across these groups. Researchers are tracking how many patients progress to active myeloma and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Leflunomide
What this could lead to
If it works, this could point toward a way to delay or prevent the progression of smoldering multiple myeloma to active disease.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply widely. Leflunomide also has known side effects like liver issues and immune suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28204, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States